跳至主要内容
临床试验/NCT01588093
NCT01588093已完成不适用

Insulin-like Growth Factor (IGF-I) Induced Muscle Glucose Uptake and Interstitial IGF-1 Concentrations.

Peter Bang1 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2011年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
8
试验地点
1
主要终点
Difference in MD (microdialysate) IGF-1 over time (expressed as AUC or peak microdialysate IGF-I) between saline and IGF-I injection.

研究概览

简要总结

Hormonal disturbances in the GH-IGF-I axis are considered important for the deterioration of glycemic control in T1DM particularly in adolescents. In addition it may have direct implications on the development of insulin resistance and long-term complications.

The Investigators hypothesis is that low circulating IGF-I and compensatory hyper-secretion of GH, in the presence of peripheral insulin excess, results in increased local IGF-I expression explaining both the deterioration in metabolic control and the increased risk for microvascular complications. Correction of imbalance in circulating and tissue-specific levels of IGF-I could lead to both better early metabolic control and to prevention of early diabetic complications in type 1 diabetic (T1DM) patients.

Aim of the present study is to validate the microdialysis technique as a useable tool to predict local biological effects of IGF-1 and to understand the pharmacokinetics of local IGF-I actions after sc injection of Increlex in type 1 diabetic patients.

详细描述

Background:

In healthy subjects, the liver extracts approximately 50 % of insulin. Therefore insulin given subcutaneously results in a relative insulin deficiency in the portal circulation of the liver, and a relative insulin excess in peripheral tissues. In comparison, normal physiological delivery of insulin from the pancreas to the portal circulation, results in markedly higher hepatic insulin exposure. The importance of hepatic insulin exposure for GH induced IGF-I synthesis comes from studies demonstrating that circulating IGF-I levels can be normalized by direct portal insulin infusion (1) or nearly normalized with intra-peritoneal insulin delivery (2). Approximately 80 % of circulating IGF-I is liver derived. Whether the GH induction of IGF-I production in other tissues such as fat, muscle and the growth plate is also insulin dependent has not been studied in humans. While locally produced IGF-I is important for linear growth, circulating IGF-I is essential for insulin sensitivity (3). Portal insulin deficiency results in uncoupling of GH induced IGF-I synthesis and subnormal circulating IGF-I levels in T1DM children with conventional therapy (4).

In newly diagnosed T1DM subcutaneous insulin treatment increases circulating IGF-I (5). The beneficial effects of 12 weeks adjuvant IGF-I treatment on metabolic control was demonstrated in conventionally insulin treated T1DM adolescents (6). There is also strong evidence for the role of IGF-I in the pathogenesis of diabetic kidney disease, atherosclerosis and proliferative retinopathy (7, 8, 9).

Interestingly, recent reports suggest an important role of IGF-I in stimulating beta cell regeneration (10). Thus a role for improvement of IGF-I in prolonging endogenous insulin secretion in the early phase of T1DM disease appears promising.

The Investigators have previously developed a microdialysis approach to measure local IGF-I protein levels from the human muscle tissue. The Investigators were in that study able to show that exercise increases local IGF-I levels. (11, 12) However, no further analysis concerning tissue-specific glucose metabolism was performed.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 23 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Type 1 diabetes duration at least two years and assumed C-peptide negativity
  • Chronological age from 18 to 25 years
  • Tanner stage > 4 (Girls: Tanner B4 or more, Boys: Testis > 15 ml)
  • Levemir or Lantus as basal analogue or CSII
  • IGF-1 < -1.0 SDS and HbA1C < 73 mmol/mol with screening or within past three months
  • Written informed consent

排除标准

  • Development of hypoglycemia that can not be controlled with increased glucose infusion-rate

研究组 & 干预措施

Saline

Placebo Comparator

干预措施: 0.9% Saline (Drug)

Increlex

Active Comparator

干预措施: Increlex (Drug)

结局指标

主要结局

Difference in MD (microdialysate) IGF-1 over time (expressed as AUC or peak microdialysate IGF-I) between saline and IGF-I injection.

时间窗: 0-4 hours from injection

次要结局

未报告次要终点

研究者

发起方
Peter Bang
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Peter Bang

Professor

Karolinska University Hospital

研究点 (1)

Loading locations...

相似试验